Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Fatty Acids Adjunctive to Aripiprazole for Pediatric Bipolar Disorder
NCT00592683Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in bipolar disorder (BD) comparing Aripiprazole plus Fish Oil with Aripiprazole plus Placebo (2 arms). Primary endpoint: Young-Mania Rating Scale at 12 weeks. Started Dec 2007; status: terminated.
02
Drugs
omega-3 fatty acid
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00592683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592683.